Research programme: virus induced cancer therapeutics - Cellestia Biotech
Latest Information Update: 27 Oct 2021
At a glance
- Originator Cellestia Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Oct 2021 Early research in Cancer in Switzerland (unspecified route) (Cellestia Biotech pipeline, October 2021)